Our wholly owned pipeline
We’re building a pipeline of differentiated, potential best-in-class and first-in-class medicines, by leveraging the power of our AI-driven drug discovery and development platform. Recursion’s internal pipeline is focused on indications with high unmet need, including oncology and rare disease.
REC-4881 is an orally bioavailable, non-ATP-competitive, allosteric small molecule inhibitor of MEK1 and MEK2 being developed to reduce polyp burden and progression to adenocarcinoma in people living with FAP, a rare tumor predisposition syndrome. There are currently no FDA-approved therapies for the treatment of FAP. MEK1/2 inhibition to target FAP was identified using phenotypic insights by the Recursion OS. In the Phase 2 TUPELO study, REC-4881 has demonstrated consistent reductions in polyp burden across the GI tract, with the most pronounced effect in the upper GI, and durable activity after treatment ended.
Learn more on clinicaltrials.gov.
REC-1245 is a highly potent RBM39 degrader being developed for the treatment of solid tumor indications and lymphoma, with multiple biomarkers being explored. RBM39 was identified using phenotypic insights from our AI-native product engine, and is a novel DDR target mimicking CDK12 loss. There are currently no RBM39 degraders approved by the FDA. In the ongoing Phase 1 DAHLIA study, REC-1245 has shown anti-tumor activity across tumor types in heavily pretreated patients, including partial responses in endometrial cancer and hepatocellular carcinoma, with a safety profile predominantly limited to manageable Grade 1/2 treatment-related adverse events.
Learn more on clinicaltrials.gov
REC-4539 is the first LSD1 inhibitor designed to be both reversible and CNS-penetrant, and is being developed for multiple solid tumor and hematology indications, including small-cell lung cancer (SCLC) and acute myeloid leukemia (AML). There are currently no LSD1 inhibitors approved by the FDA. REC-4539’s combined properties distinguish it from other LSD1 inhibitors in development, with the potential to reduce adverse events seen from on-target platelet effects.
Learn more on clinicaltrials.gov
REC-7735 is a PI3Kα H1047R mutant selective inhibitor being developed for the treatment of solid tumors including HER2- HR+ breast cancer where the PI3Kα-H1047R mutation is present. This highly selective inhibitor targets the most frequent PIK3CA mutation and a key driver of cancer. REC-7735 was designed to maximize the therapeutic window and to avoid dose-limiting hyperglycemia or other off-target AEs associated with wild-type PI3Kα inhibition. Preclinical models have shown tumor regression when used as a monotherapy treatment and when combined with standard of care.
Learn more on clinicaltrials.gov
REC-102 is an orally bioavailable, small molecule ENPP1 inhibitor, being developed for the treatment of hypophosphatasia (HPP). HPP is a rare, potentially life-threatening genetic disease, characterized by impaired mineralization of bones and teeth. Inhibiting ENPP1 reduces inorganic pyrophosphate (PPi) levels which may restore the PPi and phosphate balance needed to promote bone mineralization. With our collaborators, we have shown that ENPP1 inhibition is safe and well-tolerated by preclinical models, and for the first time demonstrated that ENPP1 is a druggable target for later-onset HPP.
Our partnered pipeline
We combine our scaled biology, precision chemistry, and automated synthesis capabilities to pave the way to transformative therapies with our partners.
.png)
- 6 program milestones achieved to date across 5 programs
- First development candidate optioned by Sanofi (October 2026): a potential first-in-class oral small molecule for a dual target in inflammatory disease expected to enter Phase 1 clinical trials in 2027
- Additional programs advancing toward development candidate and other milestones over the next 12 months
- 6 Phenomaps: 4 GI oncology, 2 neuroscience
- 1 program initiated in GI onc indication
- 1st Neuroscience target optioned
.png)
- Therapeutic area: oncology & immunology
- Identify and advance first-in-class and best-in-class programs
